Glasgow, Scotland – 11 November 2024. EnteroBiotix Limited (‘EnteroBiotix’ or the ‘Company’), a clinical-stage biotechnology company focussed on developing best-in-class full-spectrum microbiome ...

GLASGOW, Scotland, Feb. 01, 2024 (GLOBE NEWSWIRE) -- EnteroBiotix Limited (“EBX”), a clinical stage biopharmaceutical company with the premier platform for full-spectrum microbiome therapeutics, today ...

Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBSDosing of first patient of the Phase 2b 'RISE' tr ...

Glasgow, Scotland – 28 April 2025. EnteroBiotix Limited (‘EnteroBiotix’), a biopharmaceutical company developing best-in-class therapies for gut health, today announced that data from its Phase 2a ...

EBX-102 was well tolerated and showed multiple positive trends over placebo Findings support progression to a Phase 2b trial Glasgow, Scotland – 13 May 2025. EnteroBiotix Limited (‘EnteroBiotix)’ a ...

EnteroBiotix has rounded up $21.5 million in a series A financing to advance a pipeline of drugs targeting the microbiome, which is believed to play a role in overall health. With the capital, the ...

Glasgow, Scotland - 2 May 2025. EnteroBiotix Limited ('EnteroBiotix'), a clinical-stage biopharmaceutical company focussed on developing best-in-class drugs for gut health, today announced that ...

Glasgow, Scotland – 17 July 2023. EnteroBiotix Limited (“EBX”), a clinical stage company with the premier platform for full-spectrum microbiome therapeutics, today announced the appointment to its ...

ABERDEEN, Scotland--(BUSINESS WIRE)--EnteroBiotix, a leading clinical stage microbiome therapeutics company, has been granted a manufacturers ‘specials’ license from the Medicines and Healthcare ...

Glasgow, Scotland – 11 October 2022 – EnteroBiotix Limited, the premier full-spectrum microbiome therapeutics company, today announced that it has been granted a Manufacturer’s licence for ...